AlzProtect alzprotect.com


Public lists: Pharma Startups (4732)

AlzProtect is developing anti-Alzheimer drugs acting through an original mechanism of action and discovered in a collaborative work of several years at INSERM and the University of Lille 2. Its main lead molecule, AZP2006, intended for the treatment of Alzheimer disease (AD) and possibly Frontotemporal Dementia (FTD) has achieved proof of concept in animals and will enter clinical Phase 1 in early 2014. Additional backup and biomarkers to guide clinical trials are in development. The objective o...Show all

AlzProtect is developing anti-Alzheimer drugs acting through an original mechanism of action and discovered in a collaborative work of several years at INSERM and the University of Lille 2. Its main lead molecule, AZP2006, intended for the treatment ...Show all

Company (Alive / Active)

Phone:

Fax:

Parc Eurasanté
70 rue du Dr. Yersin
Loos, 59120
France

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
AlzProtect $19.9M Jan 22, 2018
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related AlzProtect Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Satoris

Redwood City, California, United States
Alive / ActiveSatoris develops tests for neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. The company is developing and commercializing neurodiagnostic tests that aim to yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective.Login to see details

Avid Radiopharmaceuticals

Philadelphia, Pennsylvania, United States
AcquiredAvid is a clinical-stage product-focused molecular imaging company with IP in the field of molecular brain imaging. Per the company, Avid has developed targeting agents to image amyloid plaques and aims to leverage these compounds for the detection of Alzheimer's disease. Avid is also developing agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB), Parkinson's disease (PD), and is also involved in research related to diabetes mel...Show allLogin to see details
See all 18 competitors